At a glance
ClinicalIndex Comparison RecordPhase 2Withdrawn· 0 enrolled
Drug / intervention
CT053PTSAdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of the Ningetinib in Advanced NSCLC With MET Exon 14 Skipping Mutations
In Brief
A Phase 2 clinical trial evaluating CT053PTSA for Advanced NSCLC. Withdrawn before enrollment.
Signals
Trial was withdrawn before enrollment
Detailed Summary
This is a phase II, Single-arm,Open-label Study evaluating the safety and efficacy of CT053PTSA in Advanced Solid Tumors With MET Exon 14 Skipping Mutations
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced NSCLC
Countries--
Collaborators--
Timeline
Phase 2WithdrawnFinished
20222023202420252026
First PostedAug 2021
Enrollment StartNov 2022
Primary CompletionSep 2024
Study CompletionDec 2024
TodayJul 2026
First PostedAug 5, 2021
Enrollment StartNov 27, 2022
Primary CompletionSep 9, 2024
Study CompletionDec 9, 2024
TodayJul 1, 2026
Enrollment to primary: 1.8 yearsPosted 4.9 years ago
Interventions
CT053PTSAdrug
CT053PTSA will be administered orally once a day